Tag: Formosa Pharmaceuticals Inc.

Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
Insights and updates

Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain

TAIPEI, Nov. 28, 2024 /PRNewswire/ — Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW) announced that the company has entered into an exclusive licensing agreement with Medvisis Switzerland AG (“Medvisis”) in Switzerland and Liechtenstein, for exclusive rights to […]

Continue Reading →
Formosa Pharmaceuticals Announces Successful Top-Line Results from CPN-303, a Phase 3 Trial in Chinese Subjects for the Treatment of Inflammation and Pain after Cataract Surgery
Insights and updates

Formosa Pharmaceuticals Announces Successful Top-Line Results from CPN-303, a Phase 3 Trial in Chinese Subjects for the Treatment of Inflammation and Pain after Cataract Surgery

TAIPEI, Nov. 4, 2024 /PRNewswire/ — Formosa Pharmaceuticals, Inc. (6838.TW) reports completion and successful top-line results from CPN-303, a Phase 3 clinical study of APP13007 (GPN00833), conducted in Chinese cataract surgery patients by licensee, Grand […]

Continue Reading →